Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
Line 4 DESCRIPTION:
Doctors at the Southeastern Regional Medical Center at CTCA seek participants with Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma to receive an investigatory vaccine therapy, Oncoquest-L. The vaccine contains an extract of the patient’s own cancer cells and an immune-stimulating protein, interleukin-2 (IL-2). It is hoped that when injected under the skin, the vaccine will enable the patient’s immune system to recognize and destroy the cancer cells. The trial will also assess the safety of the vaccine, the time from vaccine treatment until the patient requires another type of anti-lymphoma treatment, progression-free survival, and the anti-tumor immune response.
Participants will receive a total of 5 single injections of Oncoquest-L over 5 months, administered subcutaneously at 2 different sites in the upper arms or upper legs. Follow up will continue for ~ 2 years.
- Be 18 years of age and older
- Be diagnosed with Follicular lymphoma (FL) grade 1, 2, or 3a within 12 months of study enrollment
- Not be pregnant
- Willing to use contraception during the study
THE STUDY INVOLVES:
- Prescreening tests to confirm eligibility of the patient to participate.
- Participants will receive a total of 5 single injections of Oncoquest-L over 5 months: first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals
- Participants will receive an immune-promoting drug (IL-2)
- The patient will be followed closely for 2 years.
LOCATIONS AND CONTACTS:
The study site is Southeastern Regional Medical Center at CTCA in Newnan, GA. Map.
Karen Rados | 770-400-6629
Mittie Mitchell, RN | 770-400-7194
XEME Biopharma Inc.
Or go online: